This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Abiomed Inc
ABMD : NASDAQ : Health Care
$83.63 up1.12 | 1.36%
Today's Range: 80.46 - 84.66
Avg. Daily Volume: 810,400
10/09/15 - 4:00 PM ET

Financial Analysis

ABIOMED INC's gross profit margin for the first quarter of its fiscal year 2015 has increased when compared to the same period a year ago. The company grew its sales and net income significantly quarter versus same quarter a year prior, and was able to outpace the average competitor in the industry when comparing revenue growth, but not when comparing net income growth. ABIOMED INC is extremely liquid. Currently, the Quick Ratio is 5.22 which clearly shows the ability to cover any short-term cash needs. ABMD managed to increase the liquidity from the same period a year ago, despite already having very strong liquidity to begin with. This would indicate improved cash flow.

At the same time, stockholders' equity ("net worth") has greatly increased by 80.83% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit

Income Statement Q1 FY15 Q1 FY14
Net Sales ($mil)73.4348.81
EBITDA ($mil)15.85-0.92
EBIT ($mil)15.18-1.54
Net Income ($mil)8.86-1.71

Balance Sheet Q1 FY15 Q1 FY14
Cash & Equiv. ($mil)154.9287.2
Total Assets ($mil)352.01206.19
Total Debt ($mil)0.00.0
Equity ($mil)308.05170.35

Profitability Q1 FY15 Q1 FY14
Gross Profit Margin86.181.42
EBITDA Margin21.57-1.87
Operating Margin20.67-3.15
Sales Turnover0.720.92
Return on Assets35.293.57
Return on Equity40.334.32
Debt Q1 FY15 Q1 FY14
Current Ratio6.734.39
Interest Expense0.00.0
Interest Coverage0.00.0

Share Data Q1 FY15 Q1 FY14
Shares outstanding (mil)42.0240.37
Div / share0.00.0
Book value / share7.334.22
Institutional Own % n/a n/a
Avg Daily Volume804190.0617438.0


BUY. ABIOMED INC's P/E ratio indicates a discount compared to an average of 33.47 for the Health Care Equipment & Supplies industry and a significant premium compared to the S&P 500 average of 19.38. To use another comparison, its price-to-book ratio of 12.17 indicates a significant premium versus the S&P 500 average of 2.58 and a significant discount versus the industry average of 14.77. The price-to-sales ratio is well above both the S&P 500 average and the industry average, indicating a premium. Upon assessment of these and other key valuation criteria, ABIOMED INC proves to trade at a discount to investment alternatives within the industry.

1 2 3 4 5
premium   discount
  Price/Cash Flow
1 2 3 4 5
premium   discount
ABMD 31.52 Peers 33.47   ABMD 72.65 Peers 24.35

Average. An average P/E ratio can signify an industry neutral price for a stock and an average growth expectation.

ABMD is trading at a valuation on par with its peers.


Premium. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.

ABMD is trading at a significant premium to its peers.

1 2 3 4 5
premium   discount
  Price to
1 2 3 4 5
premium   discount
ABMD 85.78 Peers 22.74   ABMD NM Peers 0.78

Premium. A higher price-to-projected earnings ratio than its peers can signify a more expensive stock or higher future growth expectations.

ABMD is trading at a significant premium to its peers.


Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.

ABMD's negative PEG ratio makes this valuation measure meaningless.

1 2 3 4 5
premium   discount
  Earnings Growth
1 2 3 4 5
lower   higher
ABMD 12.17 Peers 14.77   ABMD 1389.47 Peers 7.03

Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.

ABMD is trading at a discount to its peers.


Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.

ABMD is expected to have an earnings growth rate that significantly exceeds its peers.

1 2 3 4 5
premium   discount
  Sales Growth
1 2 3 4 5
premium   discount
ABMD 14.70 Peers 5.44   ABMD 34.32 Peers 14.15

Premium. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.

ABMD is trading at a significant premium to its industry.


Higher. A sales growth rate that exceeds the industry implies that a company is gaining market share.

ABMD has a sales growth rate that significantly exceeds its peers.



Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Real Money
Try it NOW

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums

Latest Stock Upgrades/Downgrades

Top Rated Stocks Top Rated Funds Top Rated ETFs